Literature DB >> 23425503

Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes.

Christopher Kobylecki1, Serena J Counsell, Nicole Cabanel, Tobias Wächter, Federico E Turkheimer, Karla Eggert, Wolfgang Oertel, David J Brooks, Alexander Gerhard.   

Abstract

Microglial activation has been implicated in the pathogenesis of Parkinson's disease (PD) and atypical parkinsonian syndromes, and regional microstructural changes have been identified using diffusion-weighted MR imaging. It is not known how these two phenomena might be connected. We hypothesized that changes in regional apparent diffusion coefficient (rADC) in atypical parkinsonian syndromes would correlate with microglial activation. In our study we have evaluated changes in rADC in 11 healthy controls, 9 patients with PD and 11 with either multiple system atrophy or progressive supranuclear palsy. The patients also underwent [(11)C]-(R)-PK11195 positron emission tomography, a marker of microglial activation. Increased rADC was found compared to controls in the thalamus and midbrain of all parkinsonian patients, and in the putamen, frontal and deep white matter of patients with atypical parkinsonian syndromes. Putaminal rADC alone did not reliably differentiate PD from atypical parkinsonism. There was no correlation between [(11)C]-(R)-PK11195 binding potential and rADC in the basal ganglia in atypical parkinsonian syndromes. However, pontine PK11195 binding and rADC were positively correlated in atypical parkinsonism (r = 0.794, p = 0.0007), but not PD patients. In conclusion, microglial activation does not appear to contribute to the changes in putaminal water diffusivity associated with atypical parkinsonian syndromes, but may correlate with tissue damage in brainstem regions.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23425503     DOI: 10.1016/j.parkreldis.2013.01.017

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

Review 1.  New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease.

Authors:  Laura Best; Christine Ghadery; Nicola Pavese; Yen Foung Tai; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2019-04-02       Impact factor: 5.081

2.  [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers.

Authors:  Donatienne Van Weehaeghe; Michel Koole; Mark E Schmidt; Stephanie Deman; Andreas H Jacobs; Erika Souche; Kim Serdons; Stefan Sunaert; Guy Bormans; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-26       Impact factor: 9.236

Review 3.  New Imaging Markers for Movement Disorders.

Authors:  Christine Ghadery; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-03       Impact factor: 5.081

Review 4.  Imaging of neuroinflammation in parkinsonian syndromes with positron emission tomography.

Authors:  Alexander Gerhard
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

Review 5.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-28       Impact factor: 9.236

6.  Microglial activation in Parkinson's disease using [18F]-FEPPA.

Authors:  Christine Ghadery; Yuko Koshimori; Sarah Coakeley; Madeleine Harris; Pablo Rusjan; Jinhee Kim; Sylvain Houle; Antonio P Strafella
Journal:  J Neuroinflammation       Date:  2017-01-11       Impact factor: 8.322

Review 7.  Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.

Authors:  Anne-Claire Dupont; Bérenger Largeau; Maria Joao Santiago Ribeiro; Denis Guilloteau; Claire Tronel; Nicolas Arlicot
Journal:  Int J Mol Sci       Date:  2017-04-07       Impact factor: 5.923

8.  Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.

Authors:  Yuko Koshimori; Ji-Hyun Ko; Romina Mizrahi; Pablo Rusjan; Rostom Mabrouk; Mark F Jacobs; Leigh Christopher; Clement Hamani; Anthony E Lang; Alan A Wilson; Sylvain Houle; Antonio P Strafella
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

Review 9.  TSPO imaging in parkinsonian disorders.

Authors:  Alexander Gerhard
Journal:  Clin Transl Imaging       Date:  2016-04-11

Review 10.  Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies.

Authors:  Fabien Chauveau; Guillaume Becker; Hervé Boutin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-13       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.